{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:09:15Z","timestamp":1767856155808,"version":"3.49.0"},"reference-count":18,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2018,4,3]]},"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Olanzapine is an atypical antipsychotic drug commonly used for the treatment of schizophrenia. However, there are still many complications associated with the use of olanzapine, and researchers continually strive to improve the handling of data from regular therapeutic drug monitoring (TDM). The objective of this study is to optimise the individualised treatment of olanzapine by establishing a population pharmacokinetics (PopPK) model in Chinese patients with schizophrenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study integrates an extensive collection of concentration data from healthy volunteers after a single dose and a less extensive collection of samples from patients undergoing TDM. A PopPK model was developed using non-linear mixed-effects modelling. Potential covariates, including the olanzapine manufacturer and patient gender and age, were assessed during model development. A total of 616 plasma concentration levels from 22 healthy male individuals in China and 458 concentration levels from 112 male and 122 female patients with schizophrenia undergoing TDM at 12 hospitals in China were included in the analysis. The concentration profile could be best described using a two-compartment model with first-order absorption and elimination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The absorption rate (Ka) of olanzapine ranged from 2.85\u2009h\n                      <jats:sup>\u20131<\/jats:sup>\n                      to 5.39\u2009h\n                      <jats:sup>\u20131<\/jats:sup>\n                      for the different formulations. The typical absorption time delay was 0.877\u2009hour. Body weight had a considerable effect on the apparent volume of the centre compartment and showed a power relationship.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      A PopPK model of olanzapine in Chinese patients with schizophrenia was developed in this study. After determining the PK parameters of olanzapine, the results suggested that body weight exhibited a considerable impact effect on V\n                      <jats:sub>C<\/jats:sub>\n                      \/F. The impact of subjects and formulations requires further study. The PopPK model established in this study is likely to provide some information for the individualised therapy of olanzapine.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ChiCTR-TRC-10000934; Results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2017-020070","type":"journal-article","created":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T00:09:28Z","timestamp":1534550968000},"page":"e020070","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6683-943X","authenticated-orcid":false,"given":"Anning","family":"Li","sequence":"first","affiliation":[{"name":"The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangmin","family":"Ji","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation, China Food and Drug Administration, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihua","family":"Yue","sequence":"additional","affiliation":[{"name":"Institute of Mental Health, the Sixth Hospital, Key Laboratory of Mental Health, Ministry of Health, Peking University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Yan","sequence":"additional","affiliation":[{"name":"Institute of Mental Health, the Sixth Hospital, Key Laboratory of Mental Health, Ministry of Health, Peking University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Dong","sequence":"additional","affiliation":[{"name":"The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canjun","family":"Ruan","sequence":"additional","affiliation":[{"name":"The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbiao","family":"Li","sequence":"additional","affiliation":[{"name":"The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Peking University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Mental Health, the Sixth Hospital, Key Laboratory of Mental Health, Ministry of Health, Peking University, Beijing, China"},{"name":"Peking-Tsinghua Centre for Life Sciences\/ PKU-IDG\/McGovern Institute for Brain Research, Peking University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanyue","family":"Wang","sequence":"additional","affiliation":[{"name":"The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,8,17]]},"reference":[{"key":"2025121422164535000_8.8.e020070.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035458"},{"key":"2025121422164535000_8.8.e020070.2","doi-asserted-by":"publisher","DOI":"10.1177\/0004867412453625"},{"key":"2025121422164535000_8.8.e020070.3","first-page":"841","article-title":"Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review","volume":"10","author":"Xue","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2025121422164535000_8.8.e020070.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"2025121422164535000_8.8.e020070.5","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007310385"},{"key":"2025121422164535000_8.8.e020070.6","unstructured":"Bergstrom RF CJ , CErimele BJ . Biopharmaceutics integrated: summary volume. Indiana, USA: Lilly Laboratory for Clinical Research: Eli Lilly and Co."},{"key":"2025121422164535000_8.8.e020070.7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10928-005-0037-z","article-title":"Propagation of population PK and PD information using a Bayesian approach: dealing with non-exchangeability","volume":"33","author":"Dokoumetzidis","year":"2006","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2025121422164535000_8.8.e020070.8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/11532580-000000000-00000","article-title":"Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model","volume":"12","author":"Lobo","year":"2010","journal-title":"Paediatr Drugs"},{"key":"2025121422164535000_8.8.e020070.9","doi-asserted-by":"publisher","DOI":"10.1038\/ng.979"},{"key":"2025121422164535000_8.8.e020070.10","doi-asserted-by":"publisher","DOI":"10.1007\/BF01060053"},{"key":"2025121422164535000_8.8.e020070.11","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061030"},{"key":"2025121422164535000_8.8.e020070.12","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061870"},{"key":"2025121422164535000_8.8.e020070.13","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb04326.x"},{"key":"2025121422164535000_8.8.e020070.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2007.12.002"},{"key":"2025121422164535000_8.8.e020070.15","unstructured":"Thomasson HR CJ , Bergstrom RF . Oral olanzapine: safety and pharmacokineticstudy in subjects with cirrhosis. Indiana, USA: Eli Lilly and Co: Lilly Laboratory for Clinical Research, 1996."},{"key":"2025121422164535000_8.8.e020070.16","unstructured":"Bergstrom RF CB . Olazapine in subjects with and without renal failure. Indiana, USA: Eli Lilly and Co: Lilly Laboratory for Clinical Research, 1996."},{"key":"2025121422164535000_8.8.e020070.17","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937030-00001"},{"key":"2025121422164535000_8.8.e020070.18","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050527"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-020070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:16:55Z","timestamp":1765779415000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-020070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":18,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,17]]},"published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1136\/bmjopen-2017-020070"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-020070","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}